The emotional and physical impact of wet age-related macular degeneration: findings from the wAMD Patient and Caregiver Survey

Código QR

The emotional and physical impact of wet age-related macular degeneration: findings from the wAMD Patient and Caregiver Survey

Monica Varano,1 Nicole Eter,2 Steve Winyard,3 Kim U Wittrup-Jensen,4 Rafael Navarro,5 Julie Heraghty6 On behalf of the wAMD Patient and Caregiver Survey Committee members 1Department of Ophthalmology, Fondazione GB Bietti-IRCCS, Rome, Italy; 2Department of Ophthalmology, University of Mün...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Varano M, Eter N, Winyard S, Wittrup-Jensen KU, Navarro R, Heraghty J
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	wet age-related macular degeneration (wAMD) anti-VEGF agents wAMD Patient and Caregiver Survey patient-reported outcomes Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/d1157d5b5e8c4db5a356369b60ca8e3f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Physician, patient, and caregiver experience of different wet age-related macular degeneration anti-VEGF treatment regimens in Japan: a qualitative assessment
por: Iida T, et al.
Publicado: (2016)

Current barriers to treatment for wet age-related macular degeneration (wAMD): findings from the wAMD patient and caregiver survey
por: Varano M, et al.
Publicado: (2015)

Differential Circulating MicroRNA Expression in Age-Related Macular Degeneration
por: Hanan ElShelmani, et al.
Publicado: (2021)

Initiation and maintenance of a Treat-and-Extend regimen for ranibizumab therapy in wet age-related macular degeneration: recommendations from the UK Retinal Outcomes Group
por: Amoaku W, et al.
Publicado: (2018)

Age, sex, and type of medication predict the effect of anti-VEGF treatment on central retinal thickness in wet age-related macular degeneration
por: Bek T, et al.
Publicado: (2018)

Early and intermediate age-related macular degeneration: update and clinical review
por: García-Layana A, et al.
Publicado: (2017)

Neovascular age-related macular degeneration: intraocular inflammatory cytokines in the poor responder to ranibizumab treatment
por: Pongsachareonnont P, et al.
Publicado: (2018)

Association of treatment adherence with real-life VA outcomes in AMD, DME, and BRVO patients
por: Ehlken C, et al.
Publicado: (2017)

OCT Angiography-based Evaluation of the Choriocapillaris in Neovascular Age-related Macular Degeneration
por: Varsha Pramil, et al.
Publicado: (2021)

Correlation of Baseline Visual Acuity with Outcomes of Treatment with Anti-VEGF in Neovascular Age-Related Macular Degeneration
por: Veluswamy B, et al.
Publicado: (2020)

Twelve-week dosing with Aflibercept in the treatment of neovascular age-related macular degeneration
por: Garweg JG
Publicado: (2019)

Selective retina therapy and thermal stimulation of the retina: different regenerative properties - implications for AMD therapy
por: Elisabeth Richert, et al.
Publicado: (2021)

No improvement in injection frequency or in visual outcome over time in two cohorts of patients from the same Swedish county treated for wet age-related macular degeneration
por: Schroeder M, et al.
Publicado: (2017)

Clinical observations on the use of new anti-VEGF drug, conbercept, in age-related macular degeneration therapy: a meta-analysis
por: Cui C, et al.
Publicado: (2017)

Results of switchback from ranibizumab to aflibercept in patients with exudative age-related macular degeneration
por: Koike N, et al.
Publicado: (2019)

Medication Trends for Age-Related Macular Degeneration
por: Yeon-Kyoung Cho, et al.
Publicado: (2021)

Visual outcome of intravitreal ranibizumab for exudative age-related macular degeneration: timing and prognosis
por: Canan H, et al.
Publicado: (2014)

Genetics and age-related macular degeneration: a practical review for the clinician
por: Schwartz SG, et al.
Publicado: (2016)

Decreased VEGF-A and sustained PEDF expression in a human retinal pigment epithelium cell line cultured under hypothermia
por: Takeyama,Masayuki, et al.
Publicado: (2015)

Choriocapillaris Vascular Density Changes: Healthy vs. Advanced Exudative Age-Related Macular Degeneration Previously Treated with Multiple Anti-VEGF Intravitreal Injections
por: Maria Cristina Savastano, et al.
Publicado: (2021)

Anatomical and functional response after conversion to aflibercept using the treat-and-extend regimen protocol in bevacizumab treatment-resistant wet age-related macular degeneration
por: Taipale C, et al.
Publicado: (2018)

ANÁLISIS DE LA FRACCCIÓN LIPÍDICA DE LA YEMA DE HUEVOS POR AMD-HPTLC
por: Figueroa,Carolina E., et al.
Publicado: (2002)

Cost-Effectiveness of Conbercept vs. Ranibizumab for Age-Related Macular Degeneration, Diabetic Macular Edema, and Pathological Myopia: Population-Based Cohort Study and Markov Model
por: Zhuang Cui, et al.
Publicado: (2021)

Patient Preferences Associated with Anti-Vascular Endothelial Growth Factor Therapies for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema
por: Bhagat D, et al.
Publicado: (2020)

The effect of intravitreal injections on dry eye, and proposed management strategies
por: Laude A, et al.
Publicado: (2017)

Complement Factor H Loss in RPE Cells Causes Retinal Degeneration in a Human RPE-Porcine Retinal Explant Co-Culture Model
por: Angela Armento, et al.
Publicado: (2021)

Randomised, Double-blind, Comparative Clinical Study of New Ranibizumab Biosimilar in Neovascular (Wet) Age-Related Macular Degeneration
por: Apsangikar P, et al.
Publicado: (2021)

Aqueous humor cytokine levels through microarray analysis and a sub-analysis based on optical coherence tomography in wet age-related macular degeneration patients
por: Jin-Ho Joo, et al.
Publicado: (2021)

Refractive Error and Eye Health: An Umbrella Review of Meta-Analyses
por: Yin-hao Wang, et al.
Publicado: (2021)

Three-year follow-up of ranibizumab treatment of wet age-related macular degeneration: influence of baseline visual acuity and injection frequency on visual outcomes
por: Razi F, et al.
Publicado: (2016)

Management of neovascular age-related macular degeneration: Taiwan expert consensus
por: Ling Yeung, et al.
Publicado: (2021)

Extracellular vesicles released by human retinal pigment epithelium mediate increased polarised secretion of drusen proteins in response to AMD stressors
por: Miguel Flores‐Bellver, et al.
Publicado: (2021)

A Multicenter, Cross-Sectional Study of the Incidence of Major Macular Diseases That Cause Visual Impairment and Require Therapeutic Intervention in Greece: The ADVICE Study
por: Karagiannis DA, et al.
Publicado: (2020)

Three-year results of a modified photodynamic therapy procedure (Ironing PDT) for age-related macular degeneration patients with large lesions
por: Otsuji T, et al.
Publicado: (2016)

Full-thickness macular hole formation following anti-VEGF injections for neovascular age-related macular degeneration
por: Kabanarou SA, et al.
Publicado: (2017)

CXCR4-targeted liposomal mediated co-delivery of pirfenidone and AMD3100 for the treatment of TGFβ-induced HSC-T6 cells activation
por: Ullah A, et al.
Publicado: (2019)

Macular morphology and response to ranibizumab treatment in patients with wet age-related macular degeneration
por: Dervenis N, et al.
Publicado: (2016)

Ranibizumab in neovascular age-related macular degeneration: a 5-year follow-up
por: Cvetkova NP, et al.
Publicado: (2016)

Cone photoreceptor macular function and recovery after photostress in early non-exudative age-related macular degeneration
por: Rodriguez JD, et al.
Publicado: (2018)

Comment on: “Three-year follow-up of ranibizumab treatment of wet age-related macular degeneration: influence of baseline visual acuity and injection frequency on visual outcomes”
por: Kaya A
Publicado: (2016)